Could dopamine be a silent killer? by Azarov, Nick et al.
This article is online at http://ccforum.com/content/11/1/302 
 
Evidence-Based Medicine Journal Club  
EBM Journal Club Section Editor: Eric B. Milbrandt, MD, MPH  
 
Journal club critique 
Could dopamine be a silent killer? 
Nick Azarov,
1 Eric B. Milbrandt,
2 and Michael R. Pinsky
3 
 
1 Clinical Fellow, Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA 
2 Assistant Professor, Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA 
3 Professor, Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA 
 
 
Published online: 25 January 2007 
This article is online at http://ccforum.com/content/11/1/302 
© 2006 BioMed Central Ltd 
 
 
Critical Care 2006, 11: 302 (DOI 101186/cc5146) 
 
 
 
Expanded Abstract 
Citation 
Sakr Y, Reinhart K, Vincent JL, Sprung CL, Moreno R, 
Ranieri VM, De Backer D, Payen D: Does dopamine 
administration in shock influence outcome? Results of the 
Sepsis Occurrence in Acutely Ill Patients (SOAP) Study. Crit 
Care Med 2006, 34:589-597 [1]. 
Background 
The optimal adrenergic support in shock is controversial. 
We investigated whether dopamine administration 
influences the outcome from shock. 
Methods 
Design and setting: Multicenter observational cohort study 
in 198 European ICUs in 24 countries from May 1–15, 2002. 
Subjects: 1058 adults with ICU stay ≥24h and circulatory 
shock, 462 of which had septic shock. 
Intervention: None.  
Measurements: Shock was defined as hemodynamic 
compromise necessitating the administration of vasopressor 
catecholamines and septic shock the presence of shock 
plus infection. Patients were followed until death, hospital 
discharge, or for 60 days, whichever came first. Differences 
in ICU, hospital, and 30d mortality were determined 
dependent on whether a subject received dopamine, with 
secondary analysis by dobutamine, epinephrine, or 
norepinephrine use. 
Results: The intensive care unit mortality rate for shock was 
38.3% and 47.4% for septic shock. Of patients in shock, 375 
(35.4%) received dopamine (dopamine group) and 683 
(64.6%) never received dopamine. Age, gender, Simplified 
Acute Physiology Score II, and Sequential Organ Failure 
Assessment score were comparable between the two 
groups. The dopamine group had higher intensive care unit 
(42.9% vs. 35.7%, p=.02) and hospital (49.9% vs. 41.7%, 
p=.01) mortality rates. A Kaplan-Meier survival curve 
showed diminished 30 day-survival in the dopamine group 
(log rank=4.6, p=.032). In a multivariate analysis with 
intensive care unit outcome as the dependent factor, age, 
cancer, medical admissions, higher mean Sequential Organ 
Failure Assessment score, higher mean fluid balance, and 
dopamine administration were independent risk factors for 
intensive care unit mortality in patients with shock. 
Conclusion 
This observational study suggests that dopamine 
administration may be associated with increased mortality 
rates in shock. There is a need for a prospective study 
comparing dopamine with other catecholamines in the 
management of circulatory shock. 
Commentary 
Norepinephrine was the first vasopressors introduced into 
clinical practice [2]. In early use, norepineprhine was often 
used to treat shock without adequate volume resuscitation. 
Not surprisingly, many patients with shock manifested signs 
of worsened tissue perfusion following treatment with 
norepinephrine in the absence of adequate intravascular 
volume loading. Thus, when dopamine was introduced as a 
less potent vasopressor with greater inotropic activity, it was 
widely accepted and became the vasopressor of choice. 
Now, in the face of more rational resuscitation strategies, 
the relative merits of dopamine, norepinephrine, and other 
vasopressors deserve reconsideration.  
In the current study, Sakr and colleagues [1] examined 
mortality differences among ICU patients with shock 
stratified according to whether they received dopamine or 
not. In secondary analyses, patients were also stratified on 
the basis of treatment with dobutamine, epinephrine, or 
norepinephrine. The study included patients with a variety of 
causes of shock; 44% had septic shock and the remainder 
had forms of shock not associated with infection. In 
univariate analyses, the authors found that dopamine use 
was associated with greater ICU, hospital, and 30-day 
mortality. After adjusting for baseline characteristics and 
illness severity, dopamine use remained an independent 
predictor of ICU mortality regardless of whether shock was 
due to sepsis or other causes. Interestingly, epinephrine 
was also associated with greater 30-day mortality, yet 
norepinephrine and dobutamine were not. The authors 
concluded that dopamine administration may be associated 
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with increased mortality in shock and called for prospective 
randomized trials of dopamine and other catecholamines for 
the management of circulatory shock. 
This was a very well done study involving a large, well-
described cohort cared for in a variety of settings in 
approximately 25% of European ICUs. As is the case with 
most observational pharmacoepidemiology studies, there 
are a number of limitations that deserve consideration. 
Being observational in nature, this study cannot prove a 
cause and effect relationship and is intended to be 
hypothesis-generating rather than hypothesis-testing. This 
point was carefully noted by the authors. Information about 
the use of activated protein C, corticosteroids, and early 
goal-directed resuscitation were not collected, so the 
authors could not account for these therapeutic modalities 
in their analyses. Indication bias in this type of study is 
notoriously difficult to address. Simply put, in non-
randomized studies, subjects receive specific drugs for 
specific indications. These indications are often inextricably 
linked to outcome, and can therefore bias associations of 
drug use with outcome. Statistical methods used to account 
for this source of bias include multivariable modeling and 
propensity scores; the latter can be used to adjust for the 
likelihood of having received the drug of interest [3]. While 
the authors did use multivariable modeling, they did not 
include a propensity-based analysis. Doing so would have 
increased the robustness of their findings. It also would 
have been helpful if the authors considered clustering 
effects in their models. Patients in one hospital experience 
common treatment protocols delivered by shared clinicians, 
meaning that observations within a hospital are often 
correlated [4]. Failure to account for this correlation, or 
clustering, can lead to overstated statistical significance [5].  
If we assume for the moment that administration of 
dopamine does worsen the risk for a bad outcome, then we 
must ask the question: what is the reason for this 
deleterious effect? Multiple factors could be involved, 
among them: tachyarrhythmias, gut mucosal effects, neuro-
endocrine axis suppression [6,7], and immunosuppression 
[8].  
 
 
 
 
Recommendation 
Dr. Sakr and colleagues have provided very intriguing data, 
suggesting that patients in shock treated with dopamine are 
more likely to have a poor outcome than are patients treated 
with other vasopressors. These data add further support to 
findings obtained in earlier studies by Martin and colleagues 
[9,10], who showed that survival is better for patients with 
septic shock when norepinephrine rather than dopamine is 
the vasopressor employed to support blood pressure. Given 
the observational nature of the present data, results from a 
randomized, controlled trial will be needed before the 
findings can be applied to routine patient care. Such a study 
is currently underway [11]. It is expected that this trial will be 
completed in December 2010. We, like many others, 
anxiously await the results. 
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